Alanine News and Research RSS Feed - Alanine News and Research

No effect of baseline cirrhosis on long-term TDF treatment outcomes

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Research suggests that virological, serological and histological outcomes are comparable between cirrhotic and noncirrhotic patients with chronic hepatitis B virus infection undergoing long-term tenofovir disoproxil fumarate treatment. [More]
Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

A Spanish study suggests that bosutinib can help improve or maintain response in patients with chronic myeloid leukaemia after treatment failure of three previous tyrosine kinase inhibitors. [More]
FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects. [More]
HBV genotype C HBeAg seroconversion rate ‘negligible’

HBV genotype C HBeAg seroconversion rate ‘negligible’

Patients with chronic hepatitis B virus genotype C infection who are positive for hepatitis B e antigen should not delay antiviral treatment in the hope of seroconversion, Korean researchers recommend. [More]
Long-term entecavir, TDF effective in chronic HBV in real-world setting

Long-term entecavir, TDF effective in chronic HBV in real-world setting

A Turkish clinical practice study shows that entecavir and tenofovir disoproxil fumarate can effectively maintain long-term virological and biochemical responses in patients with chronic hepatitis B virus infection, both in those with and without cirrhosis. [More]
Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Hepatitis B surface antigen and hepatitis B core-related antigen levels can predict long-term response to sequential nucleos(t)ide analogue and interferon-α therapy in patients with chronic hepatitis B virus infection, research indicates. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

Response-guided addition of adefovir to lamivudine-based therapy not only maintains long-term viral suppression in Chinese chronic hepatitis B patients with compensated liver cirrhosis, research suggests, but also improves liver function. [More]
Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term tenofovir disoproxil fumarate therapy is effective in Chinese patients with chronic hepatitis B virus infection who have relapsed after treatment with multiple nucleos(t)ide analogues, research suggests. [More]
TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

Researchers from the Republic of Korea have found that the efficacy of tenofovir disoproxil fumarate monotherapy is comparable to that of TDF plus entecavir in chronic hepatitis B patients with genotypic resistance to entecavir. [More]
Long-term TDF therapy offers sustained HBV suppression without resistance

Long-term TDF therapy offers sustained HBV suppression without resistance

Patients with chronic hepatitis B virus infection can achieve sustained viral suppression with long-term tenofovir disoproxil fumarate treatment without developing resistance, shows a 7-year study. [More]
Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]
Combination treatment prevents disease progression in patients with advanced melanoma

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
UCLA research may lead to novel treatment for PH1

UCLA research may lead to novel treatment for PH1

Research by UCLA biochemists may lead to a new treatment - or even a cure - for PH1, a rare and potentially deadly genetic kidney disease that afflicts children. Their findings also may provide important insights into treatments for Parkinson's disease, Alzheimer's disease and other degenerative diseases. [More]
Thyroxine may overcome mutated thyroid hormone receptor effects

Thyroxine may overcome mutated thyroid hormone receptor effects

Patients with a mutation in the thyroid hormone receptor α gene that affects both the thyroid hormone receptor α1 and α2 protein variants have similar characteristics to patients with mutations affecting only the α1 variant, report researchers. [More]
Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). [More]
Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell carcinoma (mBCC) taking the investigational oral compound LDE225 (sonidegib) had marked and sustained tumor shrinkage after a median follow-up of 13.9 months. [More]
Advertisement
Advertisement